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Proper function of the Rev regulatory system is essential for the replication of lentiviruses, including feline immunodefi-
ciency virus (FIV) and human immunodeficiency virus type 1 (HIV-1). Specifically, Rev affects the overall stability of viral
mRNAs that encode necessary structural and enzymatic proteins. In turn, the eukaryotic initiation factor (eIF-5A) is
indispensable for Rev function and is the only known protein whose biologically active form requires the unique amino acid,
hypusine. Because 1,8-diaminooctane blocks the formation of hypusine by disrupting the cellular enzyme, deoxyhypusine
synthase, thereby preventing activation of eIF-5A, we investigated the effects of 1,8-diaminooctane on posttranscriptional
regulation. These are the first results to demonstrate that diaminooctane significantly reduced viral replication in a
dose-dependent manner, even under conditions of contact inhibition, diminishing the compound’s effect on cell proliferation.
Similarly, the addition of increased concentrations of diaminooctane caused a reduction in the expression of a Rev-dependent
CAT system without affecting a Rev-independent CAT system. At the RNA level, exposure of chronically infected CrFK cells
to increasing concentrations of diaminooctane substantially decreased the levels of unspliced and singly spliced viral mRNAs
and increased the relative amounts of multiply spliced transcripts in the cytoplasm. The findings of this study are the firstINTRODUCTION
The essential role of virus production and viral burden
in lentiviral pathogenesis has been well established
(Coffin, 1995; Ho et al., 1995; Wei et al., 1995). In feline
immunodeficiency virus (FIV), as well as in human im-
munodeficiency virus (HIV), the role of cellular enzymes
on viral replication need to be investigated more fully.
One of these enzymes, deoxyhypusine synthase, has
been targeted for its role in the synthesis of a unique
amino acid, hypusine, required for generating the biolog-
ically active form of eukaryotic initiation factor 5A (eIF-
5A) (Joe and Park, 1994; Joe et al., 1997; Park et al., 1993,
1998; Smit et al., 1989). Active eIF-5A has been impli-
cated in the function of the HIV-1 Rev transactivator
protein (Bevec and Hauber, 1997; Bevec et al., 1996; Liu
et al., 1997; Ruhl et al., 1993; Schatz et al., 1998;
Steinkasserer et al., 1995), which is required for lentivirus
replication. Thus, compounds that target deoxyhypusine
synthase may inhibit efficient production of virus.
A family of compounds, with diamine and triamine
analogs, have been shown to act as inhibitors of deoxy-
hypusine synthase (Jakus et al., 1993; Park et al., 1994).
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prevent eIF-5A from maturing into its active form (con-
taining hypusine). Deoxyhypusine synthase is the en-
zyme which catalyzes the initial step in the posttransla-
tional formation of the unique amino acid hypusine [Ne-
(4-amino-2-hydroxybutyl)lysine], found only in eIF-5A.
Deoxyhypusine synthase mediates the NAD-dependent
transfer of the butylamine moiety of the polyamine sper-
midine to the -amino group of the lys-50 residue in the
eIF-5A precursor protein to form the deoxyhypusine res-
idue. Hydroxylation of the deoxyhypusine residue by a
specific hydroxylase completes hypusine synthesis and
the maturation of eIF-5A (Park et al., 1993; Tao and Chen,
1995; Tao et al., 1994; Wolff et al., 1995).
Targeting cellular enzymes required for viral replica-
tion may be effective in lowering viral burden while
maintaining cellular integrity. Sequences encoding the
major structural proteins (Gag, Pol, and Env) of lentivi-
ruses are contained within potential introns. Without a
sufficient quantity of Rev, these transcripts are spliced,
removing the introns that encode the structural proteins,
before reaching the cytoplasm for translation (Pollard
and Malim, 1998). Consequently, replication of the virus
is dependent upon the Rev transactivating protein,
whose function is to allow transport of specific viral
RNAs from the nucleus to the cytoplasm. Rev is translo-
cated into the nuclei of infected cells where it specifically
binds as a monomer to unspliced or singly spliced tran-demonstration that FIV, similar to HIV-1, requires eIF-5A fo
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crete cis-acting sequence, the Rev responsive element
(RRE) (Daly et al., 1989; Malim et al., 1990). Once Rev has
interacted with its RRE, multimeric Rev complexes form,
arising from Rev protein–protein interactions and the
occupation of secondary RNA-binding sites (Pollard and
Malim, 1998). The formation of stable dimers appears to
be needed for interaction with eIF-5A. eIF-5A appears to
act as a specific adapter or bridging factor for binding of
ribonuclear protein complex to export receptor CRM1/
exportin 1, by which the complex is transported through
the nuclear pore in the presence of RanGTP (Bevec and
Hauber, 1997; Schatz et al., 1998; for review see Hauber,
2001). Through this pathway viral mRNAs are released
into the cytoplasm before splicing is completed, allowing
the translation of virion structural proteins.
It was reasoned that since 1,8-diaminooctane inhibits
the enzyme deoxyhypusine synthase and prevents hy-
pusine formation, it should also impede eIF-5A matura-
tion and diminish FIV Rev function. With a predominance
of inactivated eIF-5A, the Rev regulatory system would
fail to transport intact (unspliced and singly spliced) viral
mRNAs from the nucleus to the cytoplasm for translation.
With Rev function diminished, viral structural protein
translation should be limited, subsequently reducing vi-
ral replication. Here we report that this cascade specif-
ically affects the Rev regulatory system and its ability to
function properly. We have demonstrated that, through
the inhibition of deoxyhypusine synthase (with 1,8-diami-
nooctane), we can effectively reduce FIV production in
vitro without a reduction in cell proliferation. Also, we
were able to reduce the expression of a Rev-dependent
CAT reporter system without reducing expression of a
Rev-independent CAT system. At the RNA level, viral
mRNA splicing patterns in the cytoplasm of infected cells
were altered.
RESULTS
The affect of 1,8-diaminooctane on viral replication
and cell proliferation
To determine whether diaminooctane could reduce
virus production without affecting cell proliferation, both
functions were assessed simultaneously. Increasing
concentrations of diaminooctane were added to samples
containing differentially seeded, chronically infected
CrFK cells. The resulting data sets were divided by cell
density in 6- and 12-well plates. In the subconfluent
samples, both the cell proliferation and the viral replica-
tion (RT activity) decreased after the addition of diami-
nooctane (Fig. 1A). However, in confluent cultures, dia-
minooctane had no effect on cell proliferation but caused
a statistically significant reduction in FIV replication (Fig.
1B). Trypan blue staining for the control and diamino-
octane-treated cultures ranged from 95 to 98% viable
cells, with the variability being diaminooctane concen-
tration independent.
Rev function is inhibited by 1,8-diaminooctane
To determine if the decreased FIV replication related
specifically to Rev function, we used a previously de-
scribed FIV Rev-dependent CAT expression system (Phil-
lips et al., 1992). The results indicated that increasing
amounts of diaminooctane incrementally reduced the
expression of CAT, demonstrating that the Rev regulatory
complex failed to function properly (Fig. 2A). Conversely,
the FIV Rev-independent CAT expression system, pCAT
(Promega), was not affected by the addition of diamino-
octane. The data are represented in units of density as
determined from exposure to autoradiographic film with
converted product (acetylation) versus the concentration
of diaminooctane that was added.
Analysis of splicing events
To determine if increasing amounts of 1,8-diaminooctane
altered mRNA species, Northern blot analysis was per-
formed. Cytoplasmic RNA from the CrFK cells were probed
with random primer-labeled cDNA of full-length Rev, which
is present in all known FIV mRNAs (Phillips et al., 1992).
Clearly, when the higher concentrations of diaminooctane
were introduced and maintained in the cells’ media, the
amount of unspliced message decreased and the level of
multiply spliced messages increased (Fig. 3A). That is, the
bands representing unspliced messages diminished as
concentrations of diaminooctane exceeded 50 M, with a
dramatic decrease in unspliced messages in samples con-
taining 150 and 200 M; concomitantly, bands for the small,
multiply spliced messages increased.
DISCUSSION
This study is the first to demonstrate that a small
molecule, 1,8-diaminooctane (a diamine compound), can
indirectly disrupt FIV Rev function. Based on information
previously published, it is likely that diaminooctane,
through its interaction with deoxyhypusine synthase, in-
hibits the conversion of a specific lysine residue in
eIF-5A to the unique amino acid, hypusine (Park et al.,
1993, 1994; Wolff et al., 1995). This conversion is neces-
sary for the formation of active eIF-5A, which in turn is
required for proper Rev function. Therefore, it is likely
that the effects of diaminooctane on the Rev regulatory
system, although pronounced, were indirect (Bevec et al.,
1996; Ruhl et al., 1993; Schatz et al., 1998).
As Fig. 1A illustrates, the application of diaminooctane
decreased both cell proliferation and virus replication in
a dose-dependent manner. Since the rate of cell prolif-
eration can affect virus replication, it was important to
demonstrate that diaminooctane specifically lowered vi-
ral replication under conditions in which cell proliferation
was not affected. Therefore, contact inhibition was used
to limit cell proliferation. Under these conditions, diami-
nooctane significantly reduced viral replication in a con-
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FIG. 1. Effects of diaminooctane on cell proliferation and viral replication. (A) Represents the effects of 1,8-diaminooctane on subconfluent cells.
CrFK cells were chronically infected with the 34TF10 isolate of FIV. The cellular media were harvested for the Mg-dependent RT assay as a measure
of viral replication. The level of [3H]thymidine/g of protein incorporation was used as a measure of cell proliferation. (B) Represents the effects of
1,8-diaminooctane on confluent cells. Note that in the subconfluent cells both cell proliferation and viral replication were reduced by the addition of
diaminooctane. However, in the confluent cultures, only viral replication was affected. Analysis of variance (ANOVA) was performed and statistical
significance is indicated by the asterisks: *P  0.050; **P  0.010; ***P  0.001.
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centration-dependent manner without substantially alter-
ing cell proliferation (Fig. 1B).
Active eIF-5A is necessary for both cell proliferation
(Canellakis et al., 1989; Hanauske-Abel et al., 1994a; Lee
and Folk, 1998; Liao et al., 1998; Park et al., 1997) and
lentivirus replication (Liu et al., 1997; Schatz et al., 1998).
When increasing amounts of 1,8-diaminooctane were
added to subconfluent cultures, both cell proliferation
and viral replication decreased. In the absence of con-
tact inhibition, proliferation is susceptible to the diamine
treatment because of the cell’s requirement for biologi-
cally active eIF-5A for division (Fig. 1A) (Hanauske-Abel
et al., 1994b; Park et al., 1997). Once the cells have
reached confluence (i.e., nondividing due to contact in-
hibition), the antiproliferative effects of the diamine were
minimal, as demonstrated by the nearly equivalent
[3H]thymidine incorporation between the control and the
diaminooctane samples (Fig. 1B). Nondividing cells re-
quire less of the active form of eIF-5A (Torrelio et al.,
1984). However, for infected cells to produce new virus,
the active form of eIF-5A is continually required (Junker et
al., 1996; Liu et al., 1997; Schatz et al., 1998;
Steinkasserer et al., 1995). As the inactive form replaced
a greater percentage of the active form, the FIV Rev
regulatory system became increasingly unable to func-
tion properly, and the viral messages became more sus-
ceptible to multiple splicing. Thus, under conditions of
contact inhibition (Fig. 1B), diaminooctane had minimal
antiproliferative effects, while retaining its ability to dis-
rupt viral replication.
The CAT reporter assay, performed under conditions of
contact inhibition, demonstrated a selective effect of dia-
minooctane on the Rev regulatory system. In a concen-
tration-dependent manner, Rev-dependent CAT expres-
sion (Fig. 2A) was significantly reduced. Conversely, in
the Rev-independent CAT expression (pCAT) (Fig. 2B),
diaminooctane demonstrated no significant effect. These
results indicate that diaminooctane selectively modified
the FIV Rev system.
To further confirm the effects of diaminooctane on the
Rev regulatory system, the relative size of viral RNA in
the cytoplasm was examined. When Rev was present
and functioning correctly, large (unspliced) messages
were found within the cytoplasm of FIV-infected cells.
However, in the absence of Rev or a properly functioning
Rev system, the smaller (multiple spliced) messages
predominated. The Northern blot analysis in Fig. 3 dem-
onstrated a greater susceptibility of viral messages to
splicing under the pressure of diaminooctane. There was
an inverse relationship between the amount of diamino-
octane added to the cell cultures and the amount of
intact message in the cytoplasm, indicating that diami-
nooctane was specifically affecting Rev function.
In a recent study, two -hydroxypyridones, mimosine
and deferiprone, were used to inhibit deoxyhypusyl hy-
droxylase and prevent the formation of active eIF-5A
(Andrus et al., 1998). The results demonstrated that the
inhibition of deoxyhypusyl hydroxylase suppressed the
replication of HIV-1 by decreasing the quantity of Rev-
dependent mRNA and the structural protein p24. Al-
though the study of Andrus et al. used different inhibitors
that target deoxyhypusyl hydroxylase instead of deoxy-
hypusine synthase, and was conducted in an HIV-1 vs a
FIV system, the results of the present study are in agree-
ment that prevention of the formation of active eIF-5A
inhibits lentivirus replication.
Biologically active eIF-5A is required for the Rev pro-
tein to function properly (Bevec and Hauber, 1997; Bevec
et al., 1994, 1996; Junker et al., 1996; Katahira et al., 1995;
Liu et al., 1997; Ruhl et al., 1993; Steinkasserer et al.,
1995). Bevec and colleagues have shown a direct link
between eIF-5A and HIV-1 Rev (Bevec and Hauber, 1997;
Ruhl et al., 1993). The results of this study are the first to
FIG. 2. Effect of diaminooctane on the Rev-dependent and indepen-
dent CAT reporters. (A) Shows the statistically significant effect of
diaminooctane on the Rev-dependent reporter system, pFRev/FRRE/
CMV (Rev/RRE-CAT). Reporter activity in the absence of FIV Rev ranged
from 350 to 400. (B) Shows the effect of diaminooctane on the Rev-
independent reporter system, pCAT/CMV. Note that the addition of
diaminooctane decreased CAT expression in a concentration-depen-
dent manner in the Rev-dependent CAT expression system, but did not
effect the Rev-independent system. Statistical significance is indicated
by asterisks: *P  0.050.
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suggest a similar mechanism likely exists in the FIV Rev
system and indicate the validity of the FIV/cat model.
Binding of the Rev protein to the RRE is not inhibited by
inactive eIF-5A (Liu et al., 1997). The bound Rev complex,
in the absence of active eIF-5A, is unable to transport
viral mRNA out of the nucleus and into the cytoplasm
without being multiply spliced (Liu et al., 1997; Ruhl et al.,
1993). It appears that eIF-5A facilitates the binding of the
Rev/RRE complex to the CRM1/exporter 1 system, which
in turn transports the ribonuclear protein through the
nuclear pore complex (Bogerd et al., 1998; Hauber, 2001).
eIF-5A is associated with the nuclear-pore-attached fila-
ments, which radiate from the pore’s opening into the
nucleoplasm (Hauber, 2001). It is believed that through
these filaments the initial docking of the export cargo
occurs. Thus, eIF-5A may play a role in facilitating the
transport of export substrates to the nuclear pore for
CRM1/exporter 1 mediated export through the pore
channel. This whole process is dependent upon the
presence of active eIF-5A (containing the hypusine mod-
ification). For a complete review, see Hauber (2001).
Diaminooctane, through its action on deoxyhypusine
synthase, likely prevented the conversion of lysine to
hypusine and thereby prevented the formation of active
eIF-5A (Park et al., 1993, 1994; Wolff et al., 1995), which in
turn altered the efficient transportation of intron contain-
ing viral mRNA through the nuclear pore.
The highly conserved eIF-5A protein and its unique
amino acid, hypusine (Gordon et al., 1987; Park et al.,
1984), provide an interesting and informative system to
study the mechanisms involved with lentiviral replication.
The continued investigation of this lentivirus regulatory
system, utilizing indirect interactions mediated by linker
proteins, may enhance understanding of the role cofac-
tors play in viral transcript processing.
MATERIALS AND METHODS
Cell lines and viruses
For these studies, we used the Crandell feline kidney
cells (CrFK) chronically infected with 34TF10 (Phillips et
al., 1990, 1994; Talbott et al., 1989), a previously de-
scribed infectious molecular clone of FIV. FIV-34TF10
was established from a tissue culture adapted strain of
the Petaluma isolate of FIV (Pedersen et al., 1987). CrFK
cells were maintained in Dulbecco’s modification of min-
imal essential medium (DMEM) supplemented with 10%
fetal bovine serum (FBS), 2 mM glutamine, sodium pyru-
vate (0.11 mg/ml), and gentamicin sulfate (50 g/ml). A
viral stock of FIV-34TF10 was prepared by introducing 10
g of viral DNA into CrFK cells by electroporation (Talbott
et al., 1989). Viral replication was monitored by reverse
transcriptase (RT) assay, as previously described (Phil-
lips et al., 1990).
Cellular treatment
CrFK cells were seeded in 6- or 12-well plates (Corn-
ing) at two initial concentrations: subconfluent (50,000)
and confluent (100,000) cells/well. 1,8-Diaminooctane
(Sigma) was dissolved in growth media, added to the
cells, and maintained at concentrations of 50, 100, 150,
and 200 M. The cellular supernatants were harvested
every 48 h and replaced with fresh media containing the
drug.
FIG. 3. Northern blot analysis showing the specific effect of 1,8-diaminooctane on differential splicing. (A) Lanes 1 through 5 represent total
cytoplasmic RNA isolated from chronically infected CrFK cells hybridized with a FIV-specific probe. Diaminooctane concentrations were maintained
at 0, 50, 100, 150, and 200 M, respectively. (B) Total cytoplasmic RNA at the indicated concentration of diaminooctane.
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CAT assay
Transient cotransfections were carried out in 6- and
12-well plates using a Rev expression plasmid (pFRev)
and a Rev-dependent CAT expression plasmid (pFRRE).
The Rev-dependent plasmid was made by the addition of
FIV sequences that contained RRE to the 3 end of the
CAT encoding mRNA, as previously described (Mancuso
et al., 1994). A Rev-independent CAT expression plasmid
(pCAT) (Promega) was used as a control. A lipofectin-
based transfection protocol DOTAP (Boehringer Mann-
heim) was used with 10 g of plasmid DNA for each
sample. OptiMEM (Life Technologies) was the media
used during the transfections in 1-ml volumes and then
was removed after a 6-h incubation with the DOTAP.
Cells were harvested following a 48-h incubation in nor-
mal DMEM with 10% FBS. The cells were harvested with
a cell scraper, placed into ice-cold PBS, and then resus-
pended in 0.25 M Tris pH 7.5. The cells were disrupted
with two freeze/thaw cycles in dry ice/EtOH bath and
37°C water bath. The cellular lysates were incubated at
37°C for 1 h with 14C-chloramphenicol (Amersham
CUA435) as the reporter and butyryl-CoA as the sub-
strate. Samples were run on TLC plates (Baker) and
exposed to Bio-Max (Kodak) single-sided emulsion film
for clarity and densities were measured using the Inves-
tigator Series Video Capture Device (Fotodyne). The data
were then compiled and processed using the NIH/Scion
1.61 software and are represented as density units.
Proliferation assay
Chronically infected CrFK cells were seeded at sub-
confluent (50,000 cells) and confluent (100,000 cells) lev-
els in 6- or 12-well plates (as indicated). 1,8-Diamino-
octane was added at 50, 100, and 200 M concentra-
tions. Cells were maintained in media refreshed every
24 h. [3H]Thymidine was added on the third day and
incubated for 8 h, and cell-incorporated radioactivity was
measured by liquid scintillation counting. Data were ex-
pressed as mean counts per minute per microgram of
protein from quadruplicate samples.
Reverse transcriptase assay
Media harvested from cells used in the proliferation
assay on the third day were used in a RT assay to
determine the level of viral replication. Cells were
seeded as stated above, and the supernatant was har-
vested and centrifuged at 230,000 g for 45 min at 22°C.
The tubes were drained and swabbed to remove any
residual medium and the pellets were air dried. The viral
pellets were then resuspended thoroughly in 100 l of
reaction mix (20 mM DTT, 40 mM Tris, 360 mM NaCl, 2%
NP-40). The samples were freeze-thawed three times in
a dry-ice/EtOH bath to disrupt virions, and then 25 l was
mixed with an equal volume of buffer containing 40 mM
Tris–HCl, pH 8.1, 60 mM NaCl, 0.02 U poly [rA(dT)] (Phar-
macia-Biotech), 0.625 Ci [3H]dTTP (80 Ci/mmol, NEN),
and either 160 mM MgCl2 or 1.2 mM MnCl2 (negative
control). After incubation for 1.5 h at 37°C, the samples
(in quadruplicate) were spotted on Whattman DE81 filters
and washed for 5 min each in 0.1 M sodium pyrophos-
phate and then in 0.3 M ammonium formate. After a final
wash with 95% ethanol, the filters were dried under a
heat lamp and counted by liquid scintillation. Data were
expressed as counts per minute.
Northern blot
RNA was isolated from chronically infected CrFK cells
using the Trizol LS (Life Technologies) method, following
the manufacturer’s protocol. Briefly, after cells were
grown in media containing 0, 50, 100, 150, and 200 M of
1,8-diaminooctane for 3 days, supernatants were har-
vested for RT activity and the cells were harvested for
cytoplasmic RNA isolation. Intact cells were resus-
pended in ice-cold lysis solution (50 mM Tris–Cl pH 8.0,
100 mM NaCl, 5 mM MgCl2, 0.5% v/v NP-40) to separate
the cytoplasmic RNA from the nuclei. Nuclei were pel-
leted and Trizol LS solution was added to the superna-
tants for the isolation of cytoplasmic RNA. Separation
into aqueous/organic phases was followed by precipita-
tion of the RNA (aqueous phase) with isopropanol. The
RNA was resuspended in diethylpyrocarbonate (DEPC)-
treated water, and denaturing buffer (50% formamide, 2.2
M formaldehyde, and 1 MOPS buffer) was added. The
samples were incubated at 55°C for 15 min to disrupt
secondary structure and then were loaded onto an aga-
rose/formaldehyde denaturing gel (1% w/v agarose, 2.2
M formaldehyde, 1 MOPS) in loading buffer (0.25%
bromphenol blue, 0.25% xylene cyanol, 50% glycerol).
Gels were run at 5 V/cm for approximately 3 h and rinsed
to remove formaldehyde, and the RNA was blotted onto
Hybond-N (Amersham Life Science) membranes. After
overnight blotting, the membranes were crosslinked us-
ing the UV Stratalinker (Stratagene) and prehybridized for
30 min. Hybridization was accomplished using a re-
diprime (Amersham Life Science) random-primed
[33P]dCTP-labeled Rev cDNA probe in Rapid-hyb (Amer-
sham Life Science) buffer for a total of 2 h. Total RNA was
labeled for control. Blots were then rinsed, dried, and
exposed to Bio-Max (Kodak) film overnight.
ACKNOWLEDGMENTS
This work was supported by the National Institutes of Health Grants
RR10712 and MH47680. We thank John Polich, Ph.D., for assistance
with the statistical analyses.
REFERENCES
Andrus, L., Szabo, P., Grady, R. W., Hanauske, A. R., Huima-Byron, T.,
Slowinska, B., Zagulska, S., and Hanauske-Abel, H. M. (1998). Anti-
retroviral effects of deoxyhypusyl hydroxylase inhibitors: A hypusine-
102 HART ET AL.
dependent host cell mechanism for replication of human immuno-
deficiency virus type 1 (HIV-1). Biochem. Pharmacol. 55(11), 1807–
1818.
Bevec, D., and Hauber, J. (1997). Eukaryotic initiation factor 5A activity
and HIV-1 Rev function. Biol. Signals 6(3), 124–133.
Bevec, D., Jaksche, H., Oft, M., Wohl, T., Himmelspach, M., Pacher, A.,
Schebesta, M., Koettnitz, K., Dobrovnik, M., Csonga, R., Lottspeich, F.,
and Hauber, J. (1996). Inhibition of HIV-1 replication in lymphocytes
by mutants of the Rev cofactor eIF-5A. Science 271(5257), 1858–1860.
Bevec, D., Klier, H., Holter, W., Tschachler, E., Valent, P., Lottspeich, F.,
Baumruker, T., and Hauber, J. (1994). Induced gene expression of the
hypusine-containing protein eukaryotic initiation factor 5A in acti-
vated human T lymphocytes. Proc. Natl. Acad. Sci. USA 91(23),
10829–10833.
Bogerd, H. P., Echarri, A., Ross, T. M., and Cullen, B. R. (1998). Inhibition
of human immunodeficiency virus Rev and human T-cell leukemia
virus Rex function, but not Mason-Pfizer monkey virus constitutive
transport element activity, by a mutant human nucleoporin targeted
to Crm1. J. Virol. 72(11), 8627–8635.
Canellakis, Z. N., Marsh, L. L., and Bondy, P. K. (1989). Polyamines and
their derivatives as modulators in growth and differentiation. Yale
J. Biol. Med. 62(5), 481–491.
Coffin, J. M. (1995). HIV population dynamics in vivo: Implications for
genetic variation, pathogenesis, and therapy [see comments]. Sci-
ence 267(5197), 483–489.
Daly, T. J., Cook, K. S., Gray, G. S., Maione, T. E., and Rusche, J. R. (1989).
Specific binding of HIV-1 recombinant Rev protein to the Rev-respon-
sive element in vitro. Nature 342(6251), 816–819.
Gordon, E. D., Mora, R., Meredith, S. C., Lee, C., and Lindquist, S. L.
(1987). Eukaryotic initiation factor 4D, the hypusine-containing pro-
tein, is conserved among eukaryotes. J. Biol. Chem. 262(34), 16585–
16589.
Hanauske-Abel, H. M., Park, M. H., Hanauske, A. R., Popowicz, A. M.,
Lalande, M., and Folk, J. E. (1994a). Inhibition of the G1-S transition of
the cell cycle by inhibitors of deoxyhypusine hydroxylation. Biochim.
Biophys. Acta 1221(2), 115–124.
Hauber, J. (2001). Nuclear export mediated by the Rev/Rex class of
retroviral Trans-activator proteins. Curr. Top. Microbiol. Immunol.
259, 55–76.
Ho, D. D., Neumann, A. U., Perelson, A. S., Chen, W., Leonard, J. M., and
Markowitz, M. (1995). Rapid turnover of plasma virions and CD4
lymphocytes in HIV-1 infection [see comments]. Nature 373(6510),
123–126.
Jakus, J., Wolff, E. C., Park, M. H., and Folk, J. E. (1993). Features of the
spermidine-binding site of deoxyhypusine synthase as derived from
inhibition studies. Effective inhibition by bis- and mono-guanylated
diamines and polyamines. J. Biol. Chem. 268(18), 13151–13159.
Joe, Y. A., and Park, M. H. (1994). Structural features of the eIF-5A
precursor required for posttranslational synthesis of deoxyhypusine.
J. Biol. Chem. 269(41), 25916–25921.
Joe, Y. A., Wolff, E. C., Lee, Y. B., and Park, M. H. (1997). Enzyme-
substrate intermediate at a specific lysine residue is required for
deoxyhypusine synthesis. The role of Lys329 in human deoxyhy-
pusine synthase. J. Biol. Chem. 272(51), 32679–32685.
Junker, U., Bevec, D., Barske, C., Kalfoglou, C., Escaich, S., Dobrovnik,
M., Hauber, J., and Bohnlein, E. (1996). Intracellular expression of
cellular eIF-5A mutants inhibits HIV-1 replication in human T cells: A
feasibility study. Hum. Gene Ther. 7(15), 1861–1869.
Katahira, J., Ishizaki, T., Sakai, H., Adachi, A., Yamamoto, K., and Shida,
H. (1995). Effects of translation initiation factor eIF-5A on the func-
tioning of human T-cell leukemia virus type I Rex and human immu-
nodeficiency virus Rev inhibited trans dominantly by a Rex mutant
deficient in RNA binding. J. Virol. 69(5), 3125–3133.
Lee, Y. B., and Folk, J. E. (1998). Branched-chain and unsaturated
1,7-diaminoheptane derivatives as deoxyhypusine synthase inhibi-
tors. Bioorg. Med. Chem. 6(3), 253–270.
Liao, D. I., Wolff, E. C., Park, M. H., and Davies, D. R. (1998). Crystal
structure of the NAD complex of human deoxyhypusine synthase: An
enzyme with a ball-and-chain mechanism for blocking the active site.
Structure 6(1), 23–32.
Liu, Y. P., Nemeroff, M., Yan, Y. P., and Chen, K. Y. (1997). Interaction
of eukaryotic initiation factor 5A with the human immunodefi-
ciency virus type 1 Rev response element RNA and U6 snRNA
requires deoxyhypusine or hypusine modification. Biol. Signals
6(3), 166–174.
Malim, M. H., Hauber, J., Fenrick, R., and Cullen, B. R. (1988). Immuno-
deficiency virus rev trans-activator modulates the expression of the
viral regulatory genes. Nature 335(6186), 181–183.
Malim, M. H., Tiley, L. S., McCarn, D. F., Rusche, J. R., Hauber, J., and
Cullen, B. R. (1990). HIV-1 structural gene expression requires bind-
ing of the Rev trans-activator to its RNA target sequence. Cell 60(4),
675–683.
Mancuso, V. A., Hope, T. J., Zhu, L., Derse, D., Phillips, T., and Parslow,
T. G. (1994). Posttranscriptional effector domains in the Rev proteins
of feline immunodeficiency virus and equine infectious anemia virus.
J. Virol. 68(3), 1998–2001.
Park, M. H., Chung, S. I., Cooper, H. L., and Folk, J. E. (1984). The
mammalian hypusine-containing protein, eukaryotic initiation factor
4D. Structural homology of this protein from several species. J. Biol.
Chem. 259(7), 4563–4565.
Park, M. H., Joe, Y. A., and Kang, K. R. (1998). Deoxyhypusine synthase
activity is essential for cell viability in the yeast Saccharomyces
cerevisiae. J. Biol. Chem. 273(3), 1677–1683.
Park, M. H., Lee, Y. B., and Joe, Y. A. (1997). Hypusine is essential for
eukaryotic cell proliferation. Biol. Signals 6(3), 115–123.
Park, M. H., Wolff, E. C., and Folk, J. E. (1993). Hypusine: Its post-
translational formation in eukaryotic initiation factor 5A and its po-
tential role in cellular regulation. Biofactors 4(2), 95–104.
Park, M. H., Wolff, E. C., Lee, Y. B., and Folk, J. E. (1994). Antiproliferative
effects of inhibitors of deoxyhypusine synthase. Inhibition of growth
of Chinese hamster ovary cells by guanyl diamines. J. Biol. Chem.
269(45), 27827–27832.
Pedersen, N. C., Ho, E. W., Brown, M. L., and Yamamoto, J. K. (1987).
Isolation of a T-lymphotropic virus from domestic cats with an im-
munodeficiency-like syndrome. Science 235(4790), 790–793.
Phillips, T. R., Lamont, C., Konings, D. A., Shacklett, B. L., Hamson, C. A.,
Luciw, P. A., and Elder, J. H. (1992). Identification of the Rev transac-
tivation and Rev-responsive elements of feline immunodeficiency
virus. J. Virol. 66(9), 5464–5471.
Phillips, T. R., Prospero-Garcia, O., Puaoi, D. L., Lerner, D. L., Fox, H. S.,
Olmsted, R. A., Bloom, F. E., Henriksen, S. J., and Elder, J. H. (1994).
Neurological abnormalities associated with feline immunodeficiency
virus infection. J. Gen. Virol. 75, 979–987.
Phillips, T. R., Talbott, R. L., Lamont, C., Muir, S., Lovelace, K., and Elder,
J. H. (1990). Comparison of two host cell range variants of feline
immunodeficiency virus. J. Virol. 64(10), 4605–4613.
Pollard, V. W., and Malim, M. H. (1998). The HIV-1 Rev protein. Annu. Rev.
Microbiol. 52, 491–532.
Ruhl, M., Himmelspach, M., Bahr, G. M., Hammerschmid, F., Jaksche,
H., Wolff, B., Aschauer, H., Farrington, G. K., Probst, H., Bevec, D.,
and et al. (1993). Eukaryotic initiation factor 5A is a cellular target
of the human immunodeficiency virus type 1 Rev activation do-
main mediating trans-activation. J. Cell Biol. 123(6 Pt. 1), 1309–
1320.
Schatz, O., Oft, M., Dascher, C., Schebesta, M., Rosorius, O., Jaksche,
H., Dobrovnik, M., Bevec, D., and Hauber, J. (1998). Interaction of the
HIV-1 rev cofactor eukaryotic initiation factor 5A with ribosomal
protein L5. Proc. Natl. Acad. Sci. USA 95(4), 1607–1612.
Smit, M. Z., Schnier, J., Kaufman, R. J., and Hershey, J. W. (1989). Protein
synthesis initiation factor eIF-4D. Functional comparison of native
and unhypusinated forms of the protein. J. Biol. Chem. 264(31),
18527–18530.
Steinkasserer, A., Jones, T., Sheer, D., Koettnitz, K., Hauber, J., and
Bevec, D. (1995). The eukaryotic cofactor for the human immunode-
103INHIBITION OF FIV REV FUNCTION
ficiency virus type 1 (HIV-1) rev protein, eIF-5A, maps to chromosome
17p12–p13: Three eIF-5A pseudogenes map to 10q23.3, 17q25, and
19q13.2. Genomics 25(3), 749–752.
Talbott, R. L., Sparger, E. E., Lovelace, K. M., Fitch, W. M., Pedersen,
N. C., Luciw, P. A., and Elder, J. H. (1989). Nucleotide sequence and
genomic organization of feline immunodeficiency virus. Proc. Natl.
Acad. Sci. USA 86(15), 5743–5747.
Tao, Y., and Chen, K. Y. (1995). Purification of deoxyhypusine synthase
from Neurospora crassa to homogeneity by substrate elution affinity
chromatography. J. Biol. Chem. 270(1), 383–386.
Tao, Y., Skrenta, H. M., and Chen, K. Y. (1994). Deoxyhypusine synthase
assay based on the use of polyhistidine-tagged substrate and metal
chelate-affinity chromatography. Anal. Biochem. 221(1), 103–108.
Torrelio, B. M., Paz, M. A., and Gallop, P. M. (1984). Cellular proliferation
and hypusine synthesis. Exp. Cell Res. 154, 454–463.
Wei, X., Ghosh, S. K., Taylor, M. E., Johnson, V. A., Emini, E. A., Deutsch,
P., Lifson, J. D., Bonhoeffer, S., Nowak, M. A., Hahn, B. H., and et al.
(1995). Viral dynamics in human immunodeficiency virus type 1
infection [see comments]. Nature 373(6510), 117–122.
Wolff, E. C., Lee, Y. B., Chung, S. I., Folk, J. E., and Park, M. H. (1995).
Deoxyhypusine synthase from rat testis: Purification and character-
ization. J. Biol. Chem. 270(15), 8660–8666.
104 HART ET AL.
